Click on image to view larger version.

Figure 2 Symptom-limited exercise duration: dose and plasma concentration relationships. (A) Exercise duration versus ranolazine dose. Data are shown at trough (solid bars, primary end point) and peak (lined bars). Statistically significant increases were observed on each ranolazine dose versus placebo (*p < 0.005 vs. placebo; **p < 0.001 vs. placebo). A dose-response relationship was evident with greater increases at peak than at trough. Similar data were observed for time to onset of angina and time to 1 mm ST-segment depression (Table 2). (B) Exercise duration versus ranolazine plasma concentration. Mean exercise duration increases with mean plasma ranolazine concentrations. From left to right, values on each treatment at trough and peak, respectively, are represented by diamonds (placebo), squares (500 mg twice daily), circles (1,000 mg twice daily), and triangles (1,500 mg twice daily). Dotted lines represent the 95% confidence intervals around the fitted curve.